DK3632904T3 - URAT1-inhibitorer til at fremme urinsyreudskillelse - Google Patents

URAT1-inhibitorer til at fremme urinsyreudskillelse Download PDF

Info

Publication number
DK3632904T3
DK3632904T3 DK18806684.9T DK18806684T DK3632904T3 DK 3632904 T3 DK3632904 T3 DK 3632904T3 DK 18806684 T DK18806684 T DK 18806684T DK 3632904 T3 DK3632904 T3 DK 3632904T3
Authority
DK
Denmark
Prior art keywords
uric acid
acid excretion
promote uric
urat1 inhibitors
urat1
Prior art date
Application number
DK18806684.9T
Other languages
English (en)
Inventor
Dongfang Shi
Jianghua Zhu
Jie Gu
Xi Cheng
Yan Yang
He Zhou
Pengfei Li
Fan Wu
Original Assignee
Jiangsu Atom Bioscience And Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Atom Bioscience And Pharmaceutical Co Ltd filed Critical Jiangsu Atom Bioscience And Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK3632904T3 publication Critical patent/DK3632904T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18806684.9T 2017-05-26 2018-05-25 URAT1-inhibitorer til at fremme urinsyreudskillelse DK3632904T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710386922 2017-05-26
PCT/CN2018/088400 WO2018214961A1 (zh) 2017-05-26 2018-05-25 促尿酸排泄的urat1抑制剂

Publications (1)

Publication Number Publication Date
DK3632904T3 true DK3632904T3 (da) 2022-07-25

Family

ID=63352281

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18806684.9T DK3632904T3 (da) 2017-05-26 2018-05-25 URAT1-inhibitorer til at fremme urinsyreudskillelse

Country Status (11)

Country Link
US (1) US11597725B2 (da)
EP (1) EP3632904B1 (da)
JP (1) JP6915907B2 (da)
KR (1) KR102420892B1 (da)
CN (1) CN108484600B (da)
CA (1) CA3066680C (da)
DK (1) DK3632904T3 (da)
ES (1) ES2912941T3 (da)
MX (1) MX2019014078A (da)
PL (1) PL3632904T3 (da)
WO (1) WO2018214961A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
JP2022537291A (ja) * 2019-06-17 2022-08-25 フォチョン・ファーマシューティカルズ・リミテッド ヘテロ環式誘導体及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565734A (en) * 1977-05-03 1980-04-23 Laroche Navarron Sa Fused triazoles
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
AR042067A1 (es) * 2002-11-27 2005-06-08 Bayer Pharmaceuticals Corp Derivados de anilinopirazol utiles en el tratamiento de la diabetes
NZ568666A (en) * 2005-11-30 2011-09-30 Vertex Pharma [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met
US8735386B2 (en) * 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
WO2012048058A2 (en) * 2010-10-06 2012-04-12 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
GB201321743D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN106065010B (zh) * 2015-04-23 2019-01-01 镇江新元素医药科技有限公司 用于治疗或预防高尿酸血症或痛风的化合物
SG11201802010QA (en) * 2015-09-10 2018-04-27 Jiangsu Atom Bioscience And Pharmaceutical Co Ltd A group of compounds used for the treatment or prevention of hyperuricemia or gout
CN106433229A (zh) * 2016-08-29 2017-02-22 无锡双诚炭黑有限公司 油炉法炭黑反应装置及其反应方法
CN108084186B (zh) * 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用

Also Published As

Publication number Publication date
ES2912941T3 (es) 2022-05-30
JP6915907B2 (ja) 2021-08-04
CN108484600B (zh) 2022-12-13
EP3632904A4 (en) 2021-03-03
CA3066680C (en) 2022-04-12
WO2018214961A1 (zh) 2018-11-29
JP2020521757A (ja) 2020-07-27
EP3632904B1 (en) 2022-04-20
KR102420892B1 (ko) 2022-07-14
EP3632904A1 (en) 2020-04-08
CN108484600A (zh) 2018-09-04
MX2019014078A (es) 2020-08-03
US20200262832A1 (en) 2020-08-20
KR20200011974A (ko) 2020-02-04
CA3066680A1 (en) 2018-11-29
US11597725B2 (en) 2023-03-07
PL3632904T3 (pl) 2022-08-22

Similar Documents

Publication Publication Date Title
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3129487T3 (da) Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression
DK3164130T3 (da) Heteroaryle forbindelser anvendelige som inhibatorer af sumo-aktiverende enzym
DK3184519T3 (da) Syreadditionssalt af trk-hæmmende forbindelse
DK3377059T3 (da) Hæmmere af cxcr2
DK3594360T3 (da) Kolorimetrisk detektering af nukleinsyre amplifikation
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3154957T3 (da) Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3201206T3 (da) Borsyrederivater
DK3237406T3 (da) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidin-2,4-dion-derivativer der anvender adamts inhibitorer til behandling af osteoarthritis
DK3785799T3 (da) Fremstillingsfremgangsmåder til vanddispergerbare assays
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
IL256237A (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidine-5-ylidin)methyl)furan-2-yl)benzoic acid
GB2540917B (en) Solid acid scale inhibitors
IL254430A0 (en) Heterocyclic compounds are useful as TNF inhibitors
DK3481819T3 (da) Forbindelser og anvendelse deraf til reducering af urisyreniveauer
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3185696T3 (da) Forbedrede sammensætninger af hetero- og homofermentative mælkesyrebakteriearter til ensilagekonservering med dobbelt formål
DK2985275T3 (da) Fremgangsmåde til oprensning af beta-hydroxy-beta-methylsmørsyre
DK3512536T3 (da) Pd-1-peptidinhibitorer
DK3826723T3 (da) Boronsyrederivater
DK3632904T3 (da) URAT1-inhibitorer til at fremme urinsyreudskillelse
DK3672977T3 (da) Boronsyrederivater